Headline EventAnalyzer: Weekly Market Movers (to 5 Feb 2010)
Source EP Vantage
Company NeuroSearch 
Related: Accuray, Acorda Therapeutics, AMAG Pharmaceuticals, Auxilium Pharmaceuticals, Chugai, Immunomedics, Labopharm, Lupin, MannKind, Medivation, Micromet, Nutra Pharma, Pharmacyclics, Ranbaxy Laboratories, Santarus, Seikagaku, TopoTarget, XOMA 
Date February 08, 2010
 

EvaluatePharma’s EventAnalyzer delivers a weekly global round up of key events driving company valuations. 

Detailing the previous week’s top 15 market gains and losses, aligned with significant news flow driving share prices, the EventAnalyzer keeps you in touch with the latest market moves.

Top 15 Gains (%) - ranked on change in share price

      Performance: Fri 05 Feb vs. Fri 29 Jan    
Rank   Company   Listed Currency   Share Price Change   Market Cap (US$m)   Market Cap Change   Notes on Change  
1   NeuroSearch   DKK   +167%   1094   +684   3 Feb: Top-line phase III results for Huntexil, the company's lead drug for the treatment of Huntington's disease, show that the drug significantly improves voluntary and involuntary motor symptoms associated with the disease, raising hopes that the company's first product could be on the market by early 2012. Jyske Bank maintains "buy" rating and raises price target to DKK380 from DKK165.  
2   TopoTarget   DKK   +73%   130   +55   2 Feb: Company licenses North America and India rights for its phase III cancer drug, belinostat, to Spectrum Pharmaceuticals, in a co-development deal potentially worth more than $350m.  
3   Nutra Pharma   USD   +26%   128   +26   2 Feb: Company reports Q4 2009 sales of $583,955 for OTC pain reliever, Cobroxin, which beat the company's expectations given the drug's initial limited retail availability.  
4   Pharmacyclics   USD   +20%   241   +39   5 Feb: Shares rise on 5.5x average daily trading volume.  
5   Medivation   USD   +11%   1243   +127   5 Feb: Shares rise on 3x average daily trading volume, amid continuing speculation about the timing and nature of the release of phase III data on Alzheimer’s candidate Dimebon.  
6   Accuray   USD   +11%   381   +40   4 Feb [post market]: Company lifts full year sales guidance and reports rising orders for its CyberKnife Robotic Radiosurgery Systems alongside Q2 results.  
7   Auxilium Pharmaceuticals   USD   +10%   1465   +136   3 Feb: Company receives FDA approval for Xiaflex, for the treatment of adult Dupuytren's contracture; launch due in late March.  
8   Chugai   JPY   +10%   11090   +967   3 Feb: Company reports better-than-expected 2009 net profit on higher sales of its flu drug, Tamiflu, which increased nine-fold due to the spread of swine flu, and on strong sales of its cancer drugs, however, the company anticipates lower earnings for 2010 due to an expected decrease in Tamiflu sales.   
9   Acorda Therapeutics   USD   +9%   1167   +100   3 Feb: Company announces wholesale price for newly approved MS drug Ampyra, and launch of patient assistant and co-pay programmes; drug will be launched in March  
10   Lupin   INR   +8%   2932   +219   29 Jan: Company reports Q3 sales rise 31% and net profits rise 38%, driven by growth across all markets.  
11   Torrent Pharmaceuticals   INR   +7%   858   +54    
12   Micromet   USD   +7%   571   +35   4 Feb: Roth Capital upgrades rating to “buy” from "hold" with a $12 price target.
   4 Feb: Company announces it will host an R&D day on 10 Feb to outline plans for its lead product candidate blinatumomab (MT103) and provide an update on earlier stage BiTE antibodies.  
13   CK Life Sciences   HKD   +6%   614   +31    
14   Rigel Pharmaceuticals   USD   +6%   451   +26    
15   Seikagaku   JPY   +5%   645   +33   4 Feb: Shares rise on 3x average daily trading volume.  

Excludes companies with a market cap. movement of less than US$25m. 

Top 15 Losses (%) - ranked on change in share price 

      Performance: Fri 05 Feb vs. Fri 29 Jan    
Rank   Company   Listed Currency   Share Price Change   Market Cap (US$m)   Market Cap Change   Notes on Change  
1   XOMA   USD   -32%   106   -32   2 Feb: Company plans to raise $21m through the sale of 42m units at $0.50 per unit, a 23% discount to the company's closing share price of $0.65 on 1 Feb; each unit consists of one common share and a warrant to purchase just under a half-share of stock.  
2   Labopharm   CAD   -22%   119   -34   3 Feb: Shares fall despite FDA approval for antidepressant Oleptro (trazodone), on concerns about the chances of the drug's commercial success and the company securing a partner for the US market.  
3   Santarus   USD   -20%   219   -54   2 Feb: Company discloses that Par Pharmaceuticals will be willing to delay launching a generic version of acid reflux drug Zegerid until an ongoing court case rules on the patent challenge, if  Santarus posts a bond that could be charged in the event Par wins, from which it could claim damages as a result of delaying its launch. Negotiations on the matter are continuing.   
4   Mesoblast   AUD   -17%   225   -46    
5   AMAG Pharmaceuticals   USD   -14%   793   -130   4 Feb: SummerStreet Research Partners downgrades rating to "neutral" from "buy", citing possible severe allergic reactions in kidney disease patients to the company's iron replacement drug, Feraheme; the firm also lowers its sales forecasts for the drug.  
6   MannKind   USD   -14%   989   -153   1 Feb [post market]: Company reports wider-than-expected Q4 losses.  
7   3SBio   USD   -13%   220   -32    
8   Diamyd Medical    SEK   -11%   452   -54    
9   Ranbaxy Laboratories   INR   -11%   3657   -436   4 Feb: Reports claim that the company has received another warning letter from the FDA, saying that its measures to improve standards at plants manufacturing drugs for the US market have not been sufficient.  
10   Immunomedics   USD   -10%   226   -26   2 Feb: Company posts lower-than-expected results for fiscal Q2 2010 wherein it reports a decline in its profit and revenue because of decrease in license fee revenue from the company's agreement with Nycomed.  
11   Theravance   USD   -9%   631   -66    
12   ZymoGenetics   USD   -9%   427   -44    
13   The Medicines Company   USD   -9%   398   -40    
14   Seattle Genetics   USD   -9%   944   -93    
15   Enzon Pharmaceuticals   USD   -9%   413   -41    

Excludes companies with a market cap. movement of less than US$25m. 

Disclaimer:
The above analysis is based on daily share prices supplied to EvaluatePharma Ltd by a third party. EvaluatePharma Ltd accepts no responsibility or liability for the accuracy of the data presented here. Neither should any data presented here be construed as a solicitation or offer to buy or sell any securities or related financial instruments. 
 

This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
EP Vantage SM ©2010 EP Vantage Ltd